[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.50 0.28% 179.50 176.00 183.00 179.50 179.00 179.00 4,159 09:00:06
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 49.2 -56.5 -72.8 - 567

Amryt Pharma Share Discussion Threads

Showing 6851 to 6875 of 6875 messages
Chat Pages: 275  274  273  272  271  270  269  268  267  266  265  264  Older
DateSubjectAuthorDiscuss
23/9/2021
08:39
Yip looks like moving into a upward breakout
moorsie2
22/9/2021
20:09
Currently looking good on Nasdaq. Both bid and offer prices are above the magical 12, alphabravo!
papillon
21/9/2021
20:55
Nasdaq wants to break 12
alphabravo321
20/9/2021
23:02
Well considering how weak the Dow, S&P 500 and Nasdaq were today, the AMYT price on Nasdaq held up remarkably well.
papillon
19/9/2021
00:20
Look back at the Nasdaq AMYT Heikin-Ashi candlestick chart I posted on Wednesday morning (post 6701), bazworth. I have been following the Nasdaq AMYT chart closely and the "spinning top" Heikin-Ashi green candlestick recorded on Monday followed by the green candlestick on Tuesday in conjunction with the rising RSI indicated to me that the expected uptrend in the AMYT price had started. I tentatively bought my first shares on the 13th (Monday) as the AIM AMYT chart (Heikin-Ashi candlesticks and rising RSI) indicated a possible uptrend starting. I've added subsequently. free stock charts from uk.advfn.com
papillon
18/9/2021
23:50
The answer to that question, bazworth, is yes! I bought back in when the Nasdaq AMYT chart indicated that the recent downtrend had likely ended and changed to a likely uptrend (as indicated by the Heikin-Ashi candlesticks and rising RSI). free stock charts from uk.advfn.com
papillon
18/9/2021
23:05
Question is……R30;.. has Paps bought any??!!
bazworth
18/9/2021
22:25
I agree it is interesting. What I challenge though is that a 2019 article has even 1% association with market price action on 17th September 2021. It is OK to be wrong :) fallibility is human
moorsie2
18/9/2021
22:13
Moorsie218 Sep '21 - 20:09 - 6713 of 6715 0 1 0 An article from Nov 2019!? Really? >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> I believe that it still has relevance, Moorsie2 and that alphabravo321 was correct in drawing our attention to it. You obviously don't agree.
papillon
18/9/2021
20:33
But it does show that companies or investors don't have to wait until the initial date that was set ! I'm happy to be in now and wait ;) .......mind you my certificates quote the Epic FAST !!! Lol
richpassi
18/9/2021
20:31
Don't forget the FDA has already granted priority review for Filsuvez bringing the review date forward from March next year to Nov. So PDUFA date of Nov is already super quick.
bermudashorts
18/9/2021
20:09
An article from Nov 2019!? Really?
moorsie2
18/9/2021
18:53
I wonder if that is the reason, ab321, for the increased enthusiasm on Nasdaq for AMYT? hTTps://endpts.com/fda-approves-5-new-costly-drugs-well-ahead-of-pdufa-dates/
papillon
18/9/2021
13:52
Approval could come sooner than November 30thhtxps://endpts.com/fda-approves-5-new-costly-drugs-well-ahead-of-pdufa-dates/
alphabravo321
18/9/2021
13:38
For the first time since March the AMYT share price rose above the Kumo (cloud) on the Ichimoku chart (which went strongly bullish yesterday). PS The closing price yesterday was 177p, not the 180p that is indicated on the chart in the header. advfn have taken the price of a small UT trade timed at 4:35pm as the closing price so don't be surprised if the AMYT share price opens at 177p on Monday morning.
papillon
17/9/2021
15:26
If you go to the company’s website there is a corporate overview published September 14 after the capital markets presentation. This gives some quite interesting information and in my view well worth reading if you do your own research. I thought I would also give my take on the presentation tinged with info gleaned from the corporate overview. The major impression from the presentation was the absolute optimism from both the medical expert and the company that Oleogel - S10 would obtain US approval on November 30. In the meantime, the group now has two products with combined sales of over $200m, which are growing and where there are current studies which could lead to new indications and therefore higher sales. Let us assume that sales of these(Lomitapide and Myalepta) will reach sales of $300m within 4 to 5 years. At present Mycapssa revenues are very small. But the US target market is projected at $400m. The clinician said that there were very real reasons to use this product. The international market is considered to be the same size. But let us assume revenues get to $200m within 4 to 5 years. Returning to Oleogel, the clinician said that pain was really important and that patients or their carers would be likely to use it very quickly. Management has previously projected revenues of $500m. Let us assume again that is reached in 4 to 5 years. But that is not the end of the story, synergies from the Chiasma merger are estimated to be $50m, and that Chiasma would be EBIDA positive in year 1. Source overview. There is also AP103 and Chiasma’s TPE (delivery) platform. So Amryt could still be a growth company in 4 to 5 years time. On my revenues guesses, the Group could be reporting $1bn. What multiple could the market place on those. I guess a serious multiple of the current 1 times. I hope you found this of interest.
sidam
17/9/2021
12:29
The pre market price is up a tad (1.1%) on last night's closing price on Nasdaq. I wonder if the price will break up above the $12 barrier, on Nasdaq, today and the £1.80 barrier on AIM?
papillon
16/9/2021
17:48
AMYT Heikin-Ashi candlestick chart. Looking bullish. free stock charts from uk.advfn.com
papillon
16/9/2021
16:57
Well at least the vibe is positive anyway. Next two months will be interesting!
punter6
16/9/2021
13:07
Just going to copy across part of a post from lse:- 'The going rate for PVs seems to be on the up again, perhaps a knock-on effect of Covid as companies look to overcome potential delays at the FDA. Last month Prometic Biotherapuetics sold their voucher for $105m.' Https://liminalbiosciences.com/resources/press-releases-2021/liminal-biosciences-announces-sale-of-priority-review-voucher-for-usd105m
bermudashorts
15/9/2021
17:06
I not gonna say a word Pap, Shhhhh ;)
richpassi
15/9/2021
16:15
I don't want to tempt fate, but AMYT is looking good on Nasdaq.
papillon
15/9/2021
15:59
Gradually rising on Nasdaq.
papillon
15/9/2021
10:47
free stock charts from uk.advfn.com Nasdaq AMYT Heikin-Ashi candlestick chart has turned bullish again.
papillon
14/9/2021
18:13
Amryt Pharma impresses broker at Capital Markets Day Amryt Pharma has had its price target of US$40 and 'buy' rating reiterated by Canaccord after the company hosted a virtual capital markets day. Opinion leaders spoke on the near-term growth opportunities with Filsuvez in epidermolysis bullosa (EB) and Mycapssa in acromegaly, said the broker, which has underlined its optimistic view. The broker continues to expect US approval of Filsuvez in EB on its November 30 PDUFA date, which should serve as a significant catalyst for the share price. Oleogel-S10 (Filsuvez) could become the backbone of therapy for patients with epidermolysis bullosa (EB) if approved, said the speakers. Filsuvez would be the first FDA-approved therapy for the disease, while the current standard of care for EB includes costly specialised wound dressings combined with pain, itch, and infection management. Commercial launch preparations for Filsuvez are underway ahead of the PDUFA date with an EU decision also expected in December. Amryt is planning a relaunch strategy for Mycapssa (oral octreotide) in acromegaly and a phase 3 study of Mycapssa in patients with NETs (neuroendocrine tumours). Recently, Amryt also raised its full-year revenue guidance for 2021 to between US$220-225mln. "Amryt is a unique, cash-flow positive, global, commercial-stage company with two growth assets (Filsuvez and Mycapssa) anticipated to launch (or re-launch) near term," concluded Canaccord. Shares, which are listed in the UK and US, were trading at US$10.81 on Nasdaq Tuesday. Https://www.proactiveinvestors.co.uk/companies/news/960307/amryt-pharma-impresses-broker-at-capital-markets-day-960307.html
bermudashorts
Chat Pages: 275  274  273  272  271  270  269  268  267  266  265  264  Older
ADVFN Advertorial
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210924 13:15:17